Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Wholesalers Concerned over Effects of Medical Fee Cut: JPPA
February 11, 2002
- Recovery of Business Performance Stressed by President: Tsumura
February 11, 2002
- Japanese Society of Process Chemistry Created
February 11, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
February 11, 2002
- Korosho Clarifies Marketing Approval System
February 11, 2002
- Good Results Obtained in Vascular Dementia PIII Study on Aricept: Int'l Congress
February 11, 2002
- Korosho Proposes to Reduce Re-pricing Ceiling from 25% to 15%
February 11, 2002
- Pravastatin Reduces Risk of Stroke: Prof. Sacks of Harvard
February 11, 2002
- Amrubicin, Gatifloxacin Recommended for Approval
February 11, 2002
- Efficient Drug Development Expected with Human Tissue Bank: JHSF
February 11, 2002
- Korosho Considers Issuing Its Own List of Essential Drugs
February 11, 2002
- WORLD NEWS IN BRIEF
February 11, 2002
- Number of Births Continues to Decrease
February 11, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 11, 2002
- Pharmacoeconomic Data Not Reflected in NHI Pricing: Expert
February 11, 2002
- Kyu-Yu-Kai, Efco to Merge in April
February 11, 2002
- Survey Shows Marked Decreases in People's Interest in Science
February 11, 2002
- REGULATORY NEWS IN BRIEF
February 4, 2002
- Nippon Kayaku: Drug Sales Up 2.7% but Profits Plummet
February 4, 2002
- Mr Nagayama Concerned about Downward Pressure After Price Revision
February 4, 2002
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…